Stem Cell Derived Exome for Treatment of Diabetic Foot
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-90
SponsorSecond Affiliated Hospital of Guangzhou Medical University
About this trial
This trial is designed to investigate the safety and efficacy of patients with diabetic foot by using stem cell derived exome.
Eligibility criteria
Qualifiers
Clinical diagnosis of diabetic foot.
Signed informed consent before recruiting.
Age above 18 years or less than 90 years.
ECOG score < 4
Disqualifiers
Patients participated in clinical trials of equipment or drugs (signed informed consent) within 4 weeks;
Patients accompany by ascites, hepatic encephalopathy and esophageal and gastric varices bleeding;
Any serious accompanying disease, which is expected to have an unknown, impact on the prognosis, include heart disease, inadequately controlled diabetes and psychiatric disorders;
Patients have poor compliance.
Trial design
Treatments tested in this trial
- Skin drug prepared with exome originated from stem cell
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov